Genotypic characterization of 'inferred' rifampin mutations in GenoType MTBDRplus assay and its association with phenotypic susceptibility testing of Mycobacterium tuberculosis.
Antitubercular Agents
/ pharmacology
Bacterial Proteins
/ genetics
DNA-Directed RNA Polymerases
/ genetics
Drug Resistance, Multiple, Bacterial
/ genetics
Genotype
Humans
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis
/ drug effects
Phenotype
Rifampin
/ pharmacology
Sputum
/ microbiology
Tuberculosis
/ microbiology
GenoType MTBDRplus
Inferred mutations
Mycobacterium tuberculosis
RIF-AST
Rifampin
Sequencing
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
28
08
2019
revised:
10
12
2019
accepted:
17
01
2020
pubmed:
11
2
2020
medline:
11
11
2020
entrez:
11
2
2020
Statut:
ppublish
Résumé
In GenoType MTBDRplus assay [line probe assay (LPA)], when Mycobacterium tuberculosis (M. tuberculosis) sample DNA fails to hybridize to at least 1 rpoB wild-type probe and any mutation probe, it is inferred as rifampin (RIF)-resistant. In this study, we sought to identify such 'inferred' mutations in M. tuberculosis isolates (n = 203) by rpoB gene sequencing and determined their association with phenotypic resistance. D516Y, H526N, L511P mutations were associated with both phenotypically sensitive (59%, n = 38/64) and resistant (23.7%, n = 33/139) antimicrobial susceptibility testing (AST) results, whereas S531W mutation was associated with only RIF-resistant isolates (33%, n = 46/139). These results demonstrated that, at standard drug concentrations, some 'inferred' mutations may be missed by RIF-AST (phenotypically sensitive). The use of LPA permits identification of these RIF-resistant isolates, and incorporation of additional mutation probes (e.g., S531W) could further increase LPA specificity. Further studies are needed to establish the significance of the type of 'inferred' mutation with clinical/treatment outcomes.
Identifiants
pubmed: 32037037
pii: S0732-8893(19)30866-1
doi: 10.1016/j.diagmicrobio.2020.114995
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Bacterial Proteins
0
rpoB protein, Mycobacterium tuberculosis
0
DNA-Directed RNA Polymerases
EC 2.7.7.6
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114995Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.